The company is working with Morgan Stanley, BNP Paribas and Unicredit as bookrunners on the deal alongside global coordinators Deutsche Bank and Credit Suisse, the sources said.
Instone and the banks declined to comment or were not immediately available for comment.The transaction, which may value the company at 700 to 800 million euros ($845-970 mln), joins Siemens' Healthineers unit and healthcare group Dermapharm, both of which plan to go public before Easter as well. (Reporting by Arno Schuetze and Alexander Hübner; Editing by Georgina Prodhan)German property developer Instone targets March IPO: sources
TOP READS FROM THE FISCAL TIMES
-
Lawsuit saying Twitter aided Islamic State thrown out by U.S. appeals court
(Reuters) - A federal appeals court in San Francisco ruled on Wednesday that Twitter Inc is not liable to families of... -
Boeing ends Wall St.'s slide, Fed caution limits gains
(Reuters) - A surge in Boeing led Wall Street out of a two-day slump on Wednesday, but U.S. stocks pared gains in early... -
U.S. food distributors allege Tyson Foods, rivals fixed chicken prices
CHICAGO (Reuters) - Top U.S. food distributors Sysco Corp and U.S. Foods Inc have sued the country's biggest chicken...